The Effect of Pioglitazone on Neointima Volume and Inflammatory Markers

Launched by KOREA UNIVERSITY ANAM HOSPITAL · Jun 28, 2007

Keywords

ClinConnect Summary

With the introduction of the DES, the angiographic rates of restenosis have decreased dramatically but less prominently in diabetic patients. Even in the era of DES, diabetes remains a significant predictor of coronary restenosis especially in cases of small baseline and post PCI vessel size, longer stent length, current smokers, and high level of CRP. Restenosis remains a main clinical and angiographic concern after DES implantation especially in diabetic patients. Diabetes has been known as a major risk factor for in-stent restenosis after DES implantation.

1. Primary end point: Comparis...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: 18 years and above
• • Gender eligible for study: both
• • Diabetic patients either previously diagnosed or newly found diabetes.
• • Fasting blood glucose ≥ 126 mg/dl or PP2 blood glucose ≥ 200 mg/dl for newly found diabetes.
• • Patients with significant de novo coronary artery disease (diameter stenosis \> 70%) requiring stent implantation (angina pectoris and/or exercise-induced ischemia).
• • Patients with informed consent.
• Exclusion Criteria:
• • Acute ST-segment elevation myocardial infarction (MI)
• • CTO lesions
• • Left main lesions
• • Diabetic patients with the use of thiazolidinediones within 3 months
• • Previous history of PCI or bypass surgery
• • Patients with any contraindications to the treatment of thiazolidinediones
• • Pregnant or lactating patients
• • Chronic alcohol or drug abuse
• • Hepatic dysfunction
• • Renal dysfunction
• • Heart failure (EF \< 50%)
• • Expected life expectancy of \< 1 year